Details for New Drug Application (NDA): 090833
✉ Email this page to a colleague
NDA 090833 describes CARBIDOPA, LEVODOPA AND ENTACAPONE, which is a drug marketed by Norvium Bioscience, Rising, Sun Pharm, and Wockhardt Ltd, and is included in five NDAs. It is available from one supplier. Additional details are available on the CARBIDOPA, LEVODOPA AND ENTACAPONE profile page.
The generic ingredient in CARBIDOPA, LEVODOPA AND ENTACAPONE is carbidopa; entacapone; levodopa. There are eighteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the carbidopa; entacapone; levodopa profile page.
The generic ingredient in CARBIDOPA, LEVODOPA AND ENTACAPONE is carbidopa; entacapone; levodopa. There are eighteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the carbidopa; entacapone; levodopa profile page.
Summary for 090833
| Tradename: | CARBIDOPA, LEVODOPA AND ENTACAPONE |
| Applicant: | Wockhardt Ltd |
| Ingredient: | carbidopa; entacapone; levodopa |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 18.75MG;200MG;75MG | ||||
| Approval Date: | Nov 20, 2012 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 25MG;200MG;100MG | ||||
| Approval Date: | Nov 20, 2012 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 31.25MG;200MG;125MG | ||||
| Approval Date: | Nov 20, 2012 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
